Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Post by general360on May 09, 2022 2:51pm
321 Views
Post# 34667988

CORAL

CORAL
"Nowhere on the internet can I find a reference to CORAL other than in the RVX news release.  How can we be measured against a new and undefined standard, a standard that based on my search appears to have just been made up"

have no fear!  CORAL isn't some new standard, although i wouldnt put it past the inept co to invent shyte up.  lord knows, they wing it along with everything else... oh, while collecting big fat salaries....

DM needs to resign immediately.  you've had your chance old man. the fkuck outta here....NOW.

No, CORAL is the slick name of the new trial, we made that up using our best crayolas!

A Double-Blind Placebo Controlled Study to Assess the Efficacy and Safety of Oral Apabetalone in Elderly Subjects with Covid-19 Infection and High Risk for Severe Illness and to Explore the Potential to Limit Long-Term Symptoms (CORAL),


i bet it's something like

CO(vid) R(isk) A(nd) L(ong term).  - or L(imint)

give yourselves some RSU's for the clever name!  who writes this shyte up?

down 15% and sinking.... into the 20's if not by end of today, certainly by the time the official news comes out that we FAILED, but u know, we're focusing on P3! so whatever we have left after we're d-u-n running this co into the ground, we'll concentrate our resources on p3... or maybe we're just d-u-n with P2, and we'll never speak about p2 again...

ultimately, since this probably will not take off until 2023 for p3 starting, i'm anticipating now close to 90% loss from here.  i'd bet on it.  oh, i already have u say?!?!!? we're heading to pennies...

 fking mad....happy monday....
<< Previous
Bullboard Posts
Next >>